| Central neuropeptide signaling |
|
|
|
|
| Melanocortin receptor |
MK-0493 |
Merck |
Selective MC4R agonist, increasing MC3/4R signaling |
Phase II completed |
| RM-493 |
Rhythm |
Selective MC4R agonist, increasing MC3/4R signaling |
Phase II |
| NPY |
MK-0557 |
Merck |
Y5 receptor antagonist, NPY blocker |
Phase II completed |
| Velneperit (S-2367) |
Shionogi USA |
Y5 receptor antagonist, NPY blocker |
Phase III |
| Monoamine neurotransmission |
|
|
|
|
| Dopamine / norepinephrine / serotonin |
Contrave (bupropion / naltrexone) |
Orexigen |
Norepinephrine/dopamine reuptake inhibitor |
Phase III completed NDA submission |
| Intestinal peptide hormone signaling |
|
|
|
|
| GLP-1 |
Liraglutide (Victoza) |
Novo Nordisk |
GLP1R agonist, GLP-1 mimicking |
Phase III completed NDA submission |
| Byetta® (exenatide) |
Amylin |
GLP1R agonist, GLP-1 mimicking |
Phase III |
| OXM |
Qxyntomodulin (OXY-RPEG) |
Prolor |
GLP1R agonist, OXM mimicking |
Phase I recruiting |
| TKS1225 |
Thiakis / Wyeth / Pfizer |
GLP1R agonist, OXM mimicking |
Phase I |
| Pancreatic hormone signaling |
|
|
|
|
| PP |
PP1420 |
Wellcome Trust |
Pancreatic polypeptide analog |
Phase I completed |
| Amylin |
Davalintide (AC2307) |
Amylin |
Amylin mimicking |
Phase II |
| Adipose tissue hormone signaling |
|
|
|
|
| Leptin |
Metreleptin |
Amylin / Takeda |
Leptin receptor agonist |
Phase III recruiting |
| Inhibition of lipase |
|
|
|
|
| Pancreatic lipase |
Cetilistat (ATL-962) |
Alizyme / Takeda / Norgine |
Pancreatic lipase inhibitor, inhibiting intestinal lipid absorption |
Phase III completed |
